Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53

被引:21
|
作者
Heminger, Katherine [1 ]
Markey, Michael [1 ]
Mpagi, Meldrick [1 ]
Berberich, Steven J. [1 ]
机构
[1] Wright State Univ, Boonshoft Sch Med, Biochem & Mol Biol Dept, Dayton, OH 45435 USA
来源
AGING-US | 2009年 / 1卷 / 01期
关键词
p53; HdmX; Hdm2; RNAi; gene expression profiling; INTERACTING PROTEIN KINASE-2; SMALL-MOLECULE ANTAGONISTS; IN-VIVO; MDM2; ANTAGONISTS; P53-DEPENDENT APOPTOSIS; P53-MDM2; BINDING; LIGASE ACTIVITY; DOWN-REGULATION; ACTIVATION; DEGRADATION;
D O I
10.18632/aging.100008
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
While half of all human tumors possess p53 mutations, inactivation of wild-type p53 can also occur through a variety of mechanisms that do not involve p53 gene mutation or deletion. Our laboratory has been interested in tumor cells possessing wild-type p53 protein and elevated levels of HdmX and/or Hdm2, two critical negative regulators of p53 function. In this study we utilized RNAi to knockdown HdmX or Hdm2 in MCF7 human breast cancer cells, which harbor wild-type p53 and elevated levels of HdmX and Hdm2 then examined gene expression changes and effects on cell growth. Cell cycle and growth assays confirmed that the loss of either HdmX or Hdm2 led to a significant growth inhibition and G1 cell cycle arrest. Although the removal of overexpressed HdmX/2 appears limited to an anti-proliferative effect in MCF7 cells, the loss of HdmX and/or Hdm2 enhanced cytotoxicity in these same cells exposed to DNA damage. Through the use of Affymetrix GeneChips and subsequent RT-qPCR validations, we uncovered a subset of anti-proliferative p53 target genes activated upon HdmX/2 knockdown. Interestingly, a second set of genes, normally transactivated by E2F1 as cells transverse the G1-S phase boundary, were found repressed in a p21-dependent manner following HdmX/2 knockdown. Taken together, these results provide novel insights into the reactivation of p53 in cells overexpressing HdmX and Hdm2.
引用
收藏
页码:89 / 108
页数:20
相关论文
共 50 条
  • [11] Osteocalcin Gene Expression Is Regulated by Wild-Type p53
    Hankui Chen
    Emily Hays
    Jay Liboon
    Chris Neely
    Kevin Kolman
    Nalini Chandar
    Calcified Tissue International, 2011, 89 : 411 - 418
  • [12] Transduction of a wild-type p53 gene into human malignant melanoma cells
    Hakim, AA
    CANCER GENE THERAPY, 2001, 8 : S8 - S8
  • [13] Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells
    Matsubara, H
    Kimura, M
    Sugaya, M
    Koide, Y
    Gunji, Y
    Takegana, K
    Asano, T
    Ochiai, T
    Isono, K
    Sakiyama, S
    Tagawa, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 14 (06) : 1081 - 1085
  • [14] Stress-specific signatures: expression profiling of p53 wild-type and -null human cells
    Amundson, SA
    Do, KT
    Vinikoor, L
    Koch-Paiz, CA
    Bittner, ML
    Trent, JM
    Meltzer, P
    Fornace, AJ
    ONCOGENE, 2005, 24 (28) : 4572 - 4579
  • [15] Stress-specific signatures: expression profiling of p53 wild-type and -null human cells
    Sally A Amundson
    Khanh T Do
    Lisa Vinikoor
    Christine A Koch-Paiz
    Michael L Bittner
    Jeffrey M Trent
    Paul Meltzer
    Albert J Fornace
    Oncogene, 2005, 24 : 4572 - 4579
  • [16] Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
    Sugrue, MM
    Shin, DY
    Lee, SW
    Aaronson, SA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (18) : 9648 - 9653
  • [17] Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
    Kitagaki, Jirouta
    Agama, Keli K.
    Pommier, Yves
    Yang, Yili
    Weissman, Allan M.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) : 2445 - 2454
  • [18] ALTERATIONS IN TUMOR-DEVELOPMENT INVIVO MEDIATED BY EXPRESSION OF WILD-TYPE OR MUTANT P53 PROTEINS
    SHAULSKY, G
    GOLDFINGER, N
    ROTTER, V
    CANCER RESEARCH, 1991, 51 (19) : 5232 - 5237
  • [19] GAIN-OF-RESISTANCE TO CISPLATIN AND ITS CIRCUMVENTION IN OVARIAN TUMOR CELLS HARBORING WILD-TYPE P53
    Huang, Z. F.
    He, G.
    Meraz, I. M.
    Khokhar, A. R.
    Siddik, Z. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [20] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    A Vinyals
    M A Peinado
    M Gonzalez-Garrigues
    M Monzó
    R D Bonfil
    A Fabra
    Gene Therapy, 1999, 6 : 22 - 33